var _paq = window._paq = window._paq || []; /* tracker methods like "setCustomDimension" should be called before "trackPageView" */ _paq.push(['trackPageView']); _paq.push(['enableLinkTracking']); (function() { var u="https://rwrregs.matomo.cloud/"; _paq.push(['setTrackerUrl', u+'matomo.php']); _paq.push(['setSiteId', '1']); var d=document, g=d.createElement('script'), s=d.getElementsByTagName('script')[0]; g.async=true; g.data-privacy-src='//cdn.matomo.cloud/rwrregs.matomo.cloud/matomo.js'; s.parentNode.insertBefore(g,s); })();

About stuart.mccully

This author has not yet filled in any details.
So far stuart.mccully has created 625 blog entries.

Real World Evidence (RWE) 101 – The Role of RWE in Health Technology Assessments (HTAs)

RWE 101 – The Role of RWE in Health Technology Assessments (HTAs)

Real-world evidence (RWE) is becoming increasingly important in the context of health technology assessment (HTA), which is the process of evaluating the clinical and economic impact of healthcare interventions. HTA is used to inform decisions about which treatments, technologies, and interventions should be funded and made available to patients.

RWE can play an important role in HTA by providing additional data on the safety, effectiveness, and cost-effectiveness of healthcare interventions, beyond what is typically available from clinical trials. RWE can be generated from a variety of sources, including electronic health records, administrative claims data, patient registries, and other real-world data sources.

RWE can be used to supplement or replace data from clinical trials, particularly in situations where the clinical trial data is limited or may not fully reflect real-world conditions. For example, RWE can provide information on how interventions work in different patient populations, including those with comorbidities or other conditions that may not have been included in clinical trials.

In addition, RWE can provide valuable information on the long-term effectiveness and safety of interventions, as well as their impact on patient quality of life and other patient-centered outcomes. This information can be particularly important in assessing the value of interventions over the long term and in different patient populations.

Overall, RWE can play an important role in improving the quality and accuracy of HTA, by providing additional data and insights that can help to inform decisions about which healthcare interventions should be funded and made available to patients.

Share this story...

Real World Evidence (RWE) 101 – The Role of RWE in Health Technology Assessments (HTAs)2023-08-07T12:06:50+00:00

Real World Evidence (RWE) 101 – Verifying the Source of Data (Not to be Confused with Source Data Verification…Yup! Confusing!)

RWE 101 – Verifying the Source of Data (Not to be Confused with Source Data Verification…Yup! Confusing!)

Verifying the source of data is critical in the context of real world evidence (RWE) because the quality and reliability of the data are essential for generating accurate and trustworthy evidence. RWE is derived from real-world data (RWD), which is often collected from a variety of sources, including electronic health records (EHRs), claims databases, patient registries, and wearable devices.

There are several reasons why it is important to verify the source of RWD used to generate RWE:

Data quality: The quality of RWD can vary depending on the source, and it is essential to ensure that the data used to generate RWE are of high quality. Verification of the data source can help ensure that the data have been collected and managed in accordance with accepted standards and best practices.

Data completeness: Ensuring that the RWD used to generate RWE are complete and accurate is critical to the validity and reliability of the evidence. Verification of the data source can help ensure that all relevant data have been captured and that there are no gaps or inconsistencies in the data.

Data relevance: RWE is generated from RWD that may come from diverse sources, and it is important to verify that the data are relevant to the research question or hypothesis being investigated. Verification of the data source can help ensure that the data used to generate RWE are appropriate for the research question being addressed.

Data bias: RWD can be subject to various types of bias, including selection bias, measurement bias, and confounding bias. Verification of the data source can help identify potential sources of bias and enable appropriate adjustments to be made to the analysis to account for any bias.

In summary, verifying the source of data used to generate RWE is critical to ensure that the evidence generated is accurate, reliable, and trustworthy. It can help ensure that the data are of high quality, complete, relevant, and free from bias, which are all essential for generating high-quality evidence that can inform clinical decision-making and healthcare policy.

Share this story...

Real World Evidence (RWE) 101 – Verifying the Source of Data (Not to be Confused with Source Data Verification…Yup! Confusing!)2023-08-07T11:35:44+00:00

Real World Evidence (RWE) 101 – Challenges in RWE Generation (Regulatory Grade RWE?)

RWE 101 – Challenges in RWE Generation (Regulatory Grade RWE?)

Real-world evidence (RWE) refers to data derived from real-world sources such as electronic health records, claims data, and patient-generated data, among others. The use of RWE has gained popularity in recent years as a means of providing insights into real-world patient experiences and improving healthcare decision-making. However, generating high-quality RWE presents several challenges, including:

[1] Data quality: The quality of RWE can vary significantly depending on the source of the data. For example, electronic health records may contain incomplete or inaccurate information, and claims data may not capture all relevant clinical information. Ensuring the accuracy and completeness of RWE requires careful validation and quality control measures.

[2] Data privacy and security: RWE often contains sensitive patient information, which raises concerns about data privacy and security. The use of RWE must comply with privacy regulations such as the Health Insurance Portability and Accountability Act (HIPAA) and the General Data Protection Regulation (GDPR) to protect patient confidentiality and prevent data breaches.

[3] Bias: RWE can be subject to bias due to differences in patient populations, data collection methods, and confounding factors. Addressing these sources of bias requires careful study design and statistical analysis to ensure that the results are accurate and unbiased.

[4] Data interoperability: RWE often comes from multiple sources, each with different data formats and structures. Ensuring interoperability between different data sources can be a significant challenge, requiring the use of standardized data formats and protocols.

[5] Ethics and consent: The use of RWE raises ethical concerns about patient consent and the potential for unintended consequences, such as stigmatization or discrimination. Ensuring that patients are informed and consent to the use of their data is critical to maintaining trust and ethical practice.

Overall, generating high-quality RWE requires careful attention to data quality, privacy and security, bias, data interoperability, and ethics and consent. Addressing these challenges can help to unlock the full potential of RWE in improving healthcare decision-making and patient outcomes.

Share this story...

Real World Evidence (RWE) 101 – Challenges in RWE Generation (Regulatory Grade RWE?)2023-08-07T11:29:05+00:00

Real World Evidence (RWE) 101 – Challenges Pharma Companies Face when Using RWE to Support Marketing Authorisations

RWE 101 – Challenges Pharma Companies Face when Using RWE to Support Marketing Authorisations

Real-world evidence (RWE) studies include observational studies that uses data collected in real-world settings to investigate the safety and effectiveness of drugs and medical devices. While RWE studies can provide valuable insights into the use of medications in real-world settings, pharmaceutical companies face several challenges when using these studies to support marketing authorizations:

1. Data quality and availability: The quality and availability of real-world data can be a significant challenge for pharmaceutical companies when running RWE studies. Data sources may be incomplete, inconsistent, or difficult to access, making it difficult to draw accurate conclusions from the data.

2. Data privacy and confidentiality: Data privacy and confidentiality regulations such as GDPR can make it difficult to obtain and use patient data for RWE studies. Companies may need to navigate complex legal frameworks to obtain the data they need while ensuring that patient privacy is protected.

3. Study design and bias: RWE studies are observational and not randomized controlled trials, which makes them more susceptible to bias. Companies need to carefully design and conduct RWE studies to minimize the risk of bias and ensure that the results are reliable and representative of real-world settings.

4. Data analysis and interpretation: Analyzing and interpreting RWE data can be challenging due to the complexity of the data and the potential for bias. Companies may need to employ advanced statistical techniques to ensure that the data is analyzed accurately and that the results are valid and reliable.

5. Regulatory acceptance: Regulatory authorities may be hesitant to accept RWE studies as evidence to support marketing authorizations. Companies need to work closely with regulatory authorities to ensure that their RWE studies meet the necessary standards for regulatory acceptance.

In conclusion, pharmaceutical companies face several challenges when running RWE studies to support marketing authorizations. To overcome these challenges, companies need to carefully design and conduct studies, ensure data quality and privacy, and work closely with regulatory authorities to demonstrate the validity and reliability of their results.

Share this story...

Real World Evidence (RWE) 101 – Challenges Pharma Companies Face when Using RWE to Support Marketing Authorisations2023-08-07T11:23:22+00:00

Real World Evidence (RWE) 101 – Acknowledgement of the Limitations of Clinical Trials and RWE Studies

RWE 101 – Acknowledgement of the Limitations of Clinical Trials and RWE Studies

Clinical trials are experiments designed to test the safety and efficacy of new treatments or interventions in a controlled setting. The results of these trials are used to make decisions about whether or not to approve new drugs or treatments for use in the general population.

However, it’s important to recognize that the results of clinical trials may have limitations when it comes to their generalizability to the larger population. This is because clinical trials are typically conducted under controlled conditions, which may not accurately reflect the real-world conditions in which the treatment or intervention will be used.

Some of the limitations of clinical trial results in terms of generalizability to the larger population include:

Limited patient population: Clinical trials often have strict inclusion and exclusion criteria, which can limit the types of patients who are eligible to participate. This means that the results may not be generalizable to patients who do not meet these criteria.

Short follow-up time: Clinical trials are often conducted over a relatively short period of time, which may not be long enough to capture the long-term effects of the treatment or intervention.

Controlled setting: Clinical trials are conducted in a controlled setting, which may not accurately reflect the real-world conditions in which the treatment or intervention will be used.

Selective reporting [Controversial]: Clinical trial results may be subject to selective reporting, where only the most favorable outcomes are reported, while negative results are suppressed.

Real-world evidence (RWE) refers to data collected outside of clinical trials, such as data from electronic health records, insurance claims, and patient registries. RWE can provide important insights into how treatments or interventions work in real-world settings, and can help to address some of the limitations of clinical trial results in terms of generalizability.

However, it’s important to recognize that RWE also has its own limitations, such as the potential for confounding and bias, as well as issues related to data quality and completeness. Therefore, it’s important to carefully consider the limitations and potential biases of both clinical trial results and real-world evidence when making decisions about treatments or interventions for the larger population.

Share this story...

Real World Evidence (RWE) 101 – Acknowledgement of the Limitations of Clinical Trials and RWE Studies2023-08-07T11:13:47+00:00

Real World Evidence (RWE) 101 – Is ‘Retrospective Data’ the Same as ‘Secondary Use of Existing Data’?

RWE 101 – Is ‘Retrospective Data’ the Same as ‘Secondary Use of Existing Data’?

Retrospective data generally refers to data that has already been collected for another purpose and is being used retrospectively to answer a new research question. This data can come from various sources, such as electronic health records, claims databases, or patient registries, and is often used to generate RWE.

On the other hand, secondary use of existing data refers to the practice of using existing data for a purpose other than the one for which it was originally collected. This can include using data from clinical trials for post-market surveillance or using data from a patient registry for comparative effectiveness research.

While retrospective data can be one type of existing data that is used for secondary purposes, not all secondary uses of data involve retrospective data. For example, prospective data collected for one purpose, such as routine clinical care, can be used for secondary purposes, such as generating RWE.

In summary, retrospective data and secondary use of existing data are related but not interchangeable terms in the context of RWE. Retrospective data is a type of existing data that can be used for secondary purposes, but not all secondary uses of data involve retrospective data.

Share this story...

Real World Evidence (RWE) 101 – Is ‘Retrospective Data’ the Same as ‘Secondary Use of Existing Data’?2023-08-07T23:11:48+00:00

Real World Evidence (RWE) 101 – EHDS and GDPR – How does GDPR support the secondary use of existing health data for the purposes of scientific research?

RWE 101 – EHDS and GDPR – How does GDPR support the secondary use of existing health data for the purposes of scientific research?

The GDPR (General Data Protection Regulation) includes provisions that support the secondary use of existing health data for scientific research purposes, while also protecting the privacy and data protection rights of individuals.

One of the key ways that the GDPR supports the secondary use of health data for research is through the concept of “legitimate interests”. Article 6(1)(f) of the GDPR allows for the processing of personal data if it is necessary for the legitimate interests of the data controller or a third party, provided that those interests do not override the fundamental rights and freedoms of the data subject. Scientific research can be considered a legitimate interest, provided that appropriate safeguards are in place to protect individuals’ rights and freedoms.

In addition, the GDPR includes provisions that specifically address the use of health data for scientific research. For example, Article 9(2)(j) allows for the processing of special categories of personal data, such as health data, for scientific research purposes, provided that appropriate safeguards are in place.

The GDPR also requires that data controllers implement appropriate technical and organizational measures to ensure the security and confidentiality of personal data, including health data. This includes requirements for data pseudonymization and encryption, as well as procedures for data breach notification.

Overall, the GDPR strikes a balance between protecting individuals’ privacy and data protection rights, and supporting the important public interest in scientific research. By providing a framework for the responsible and transparent use of health data for research purposes, the GDPR can help to facilitate the development of new treatments and interventions that can improve public health outcomes.

Share this story...

Real World Evidence (RWE) 101 – EHDS and GDPR – How does GDPR support the secondary use of existing health data for the purposes of scientific research?2023-08-07T23:09:58+00:00

Real World Evidence (RWE) 101 – Federated Clinical Data

RWE 101 – Federated Clinical Data

Federated clinical data refers to clinical data that is distributed across multiple organizations or entities, such as hospitals, clinics, research institutions, or public health agencies. This data may include patient demographic information, medical history, clinical diagnoses, laboratory results, and treatment outcomes, among other types of data.

Federated clinical data allows for the integration of data from multiple sources, which can provide a more comprehensive view of patient health and disease patterns. It also enables healthcare organizations and researchers to collaborate and share data in a secure and efficient manner.

In a federated clinical data model, each organization retains control over its own data, while sharing selected data with other entities for specific purposes, such as research studies or public health surveillance. This approach helps to ensure patient privacy and data security, while still allowing for the sharing of valuable information to advance healthcare and medical research.

The use of federated clinical data is becoming increasingly common as healthcare organizations seek to harness the power of big data and machine learning to improve patient outcomes, develop new treatments, and reduce healthcare costs.

Share this story...

Real World Evidence (RWE) 101 – Federated Clinical Data2023-08-07T23:08:55+00:00

Real World Evidence (RWE) 101 – The European Health Data Space (EHDS)

RWE 101 – The European Health Data Space (EHDS)

The European Health Data Space (EHDS) is a proposed initiative by the European Union to create a secure and cross-border platform for the sharing and use of health data in the European Union. The EHDS aims to improve the quality and accessibility of health data, promote innovation in healthcare, and support research and innovation in the field of health.

The EHDS will build on existing initiatives and policies related to health data in the EU, including the General Data Protection Regulation (GDPR), the Electronic Health Record Exchange Format (EHRxf), and the European Health Insurance Card (EHIC). The initiative will also leverage emerging technologies, such as artificial intelligence and blockchain, to enhance the security, interoperability, and utility of health data.

The EHDS will focus on several key areas of health data, including electronic health records (EHRs), patient registries, medical imaging data, genomic data, and health administrative data. The initiative will establish a legal and technical framework for the sharing and use of this data, while ensuring that data privacy and security are maintained.

One of the key objectives of the EHDS is to promote the use of health data for research and innovation in healthcare. The initiative will facilitate the sharing of health data across borders and promote collaboration among researchers, clinicians, and industry partners. This is expected to lead to the development of new treatments, therapies, and medical devices, as well as improvements in healthcare delivery and outcomes.

The EHDS will also aim to improve the quality and accessibility of healthcare services by providing clinicians and patients with access to comprehensive and up-to-date health information. This will support more effective and personalized treatment decisions, as well as more efficient and coordinated healthcare delivery.

Overall, the European Health Data Space is an ambitious initiative that seeks to leverage the potential of health data to improve healthcare and drive innovation in the field. While the initiative is still in its early stages, it has the potential to transform healthcare in the European Union and to establish the EU as a leader in the use of health data for the public good.

Share this story...

Real World Evidence (RWE) 101 – The European Health Data Space (EHDS)2023-08-07T23:07:39+00:00

Real World Evidence (RWE) 101 – The Impact of the EMAs Data Quality Framework on RWE

RWE 101 – The Impact of the EMAs Data Quality Framework on RWE

The EMA (European Medicines Agency) data quality framework provides a set of guidelines and principles for ensuring high-quality data in real-world evidence (RWE) studies in the context of EU medicines regulation. The framework aims to promote the use of RWE in the assessment of medicines, and to ensure that RWE studies are conducted in a rigorous and reliable manner.

The impact of the EMA data quality framework on RWE can be significant. By promoting high-quality data collection and analysis in RWE studies, the framework can help to ensure that the results of such studies are reliable and can be used to inform regulatory decision-making. This, in turn, can facilitate the timely access of patients to new treatments and can help to improve public health outcomes.

The framework encourages the use of transparent and reproducible methods in RWE studies, which can help to ensure that the results are credible and trustworthy. The use of standardized data collection and analysis methods can also facilitate the comparison of results across different studies and settings, which can help to build a more comprehensive understanding of the safety and efficacy of medicines.

Overall, the EMA data quality framework can help to promote the use of RWE in medicines regulation and improve the quality and reliability of RWE studies. This can have a positive impact on public health by facilitating timely access to new treatments and improving the understanding of the safety and efficacy of medicines.

Share this story...

Real World Evidence (RWE) 101 – The Impact of the EMAs Data Quality Framework on RWE2023-08-07T23:06:32+00:00
Help

About Us

Contact Us

Our Values

SSO Login

Follow Us

Newsletter

LinkedIn

[…]

Legal Info

Privacy Policy

Terms and Conditions

Copyright 2026 | Real-World Research Limited | All Rights Reserved |

This website uses cookies and third party services. Settings OK Reject

Cookies

We use analytical tools (Google Analytics) to help us improve the user experience. We DO NOT sell or use any of this data for any purpose beyond improving the design and usability of our own website (rwr-regs.com).
Go to Top